Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 388-394

  Aitchison, Katherine J ^a   Munro, Janet ^a   Wright, Padraig ^a   Smith, Shulabade ^a   Makoff, Andrew J ^a   Sachse, Christoph ^b   Sham, Pak C ^a   Murray, Robin M ^a   Collier, David A ^a   Kerwin, Robert W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

CYP2D6; Genotype; Metabolism; Pharmacokinetics; Treatment refractory; Typical antipsychotics

Indexed keywords

CLOZAPINE; CYTOCHROME P450; NEUROLEPTIC AGENT;

ALLELE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; DRUG HYDROXYLATION; GENE DUPLICATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL ANALYSIS; TREATMENT FAILURE;

ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; HUMANS; HYDROXYLATION; SCHIZOPHRENIA; TREATMENT FAILURE;

EID: 0032821401     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00006.x     Document Type: Article

References (41)

1. Dahl M-L, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993; 3: 61-70.
2. Agúndez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57: 265-269.
3. Jerling M, Mellé Y, Mentré F, Mallet A. Population pharmacokinetics of northptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 - an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1994; 38: 453-462.
4. Bertilsson L, Dahl ML, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine: letter. Lancet 1993; 341: 63.
5. Johansson I, Lundqvist E, Bertisson L, Dahl ML, Sjöqvist F, Ingelman Sundberg M. Inherited amplification of an active gene in the cytocrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-11829.
6. Dahl M-L, Johansson I, Bertilsson L, Ingelman Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516-520.
7. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
8. Løvlic R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolisers of debrisoquine: characterisation and PCR-based detection of alleles with duplication of the CYP2D6, gene. FEBS Lett 1996; 392: 30-34.
9. Masimirembwa CM, Johansson I, Hasler JA, Ingelman Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993; 3: 275-280.
10. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-293.
11. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-532.
12. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxlation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10: 545-558.
13. Dahl M-L, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M. Sjöqvist F. Analysis of the CYP2D6 gent in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51: 12-17.
14. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease: letter. Lancet 1992; 341: 63.
15. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5: 215-223.
16. Johansson I, Lundqvist E, Dahl M-L, Ingelman Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmarogenetics 1996; 6: 351-355.
17. Dahl-Puustinen ML, Lidén A, Alm C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78-81.
18. Dahl M-L, Ekqvist B, Widén J, Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegrates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991; 84: 99-102.
19. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 1985; 12: 443-448.
20. Spina E, Martines C, Caputi AO, et al. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 1991; 41: 467-470.
21. Muralidharan G, Cooper JK, Hawes EM, et al. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Eur J Clin Pharmacol 1996; 50: 121-128.
22. Llerena A, Alm C, Dahl M-L, Ekqvist B, Bertisson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992; 14: 92-97.
23. Chakraborty BS, Hubbard JW, Hawes EM, et al. Interconversion between haloperidol and reduced haloperidol in healthy volunteers. Eur J Clin Pharmacol 1989; 37: 45-48.
24. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (spartcine/debdsoquine monooxygenase). Br J Clin Pharmacol 1991; 31: 655-660.
25. Young D, Midha KK, Fossler MJ, et al. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6. Eur J Clin Pharmacol 1993; 44: 433-438.
26. Fang J, Baker GB, Silverstone PH, et al. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cellular Molec Neurobiol 1997; 17: 227-233.
27. Pan LP, De Vriendt C, Belpaire FM. In-vitro characterisation of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 1998; 8: 383-389.
28. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152: 173-178.
29. Suzuki A, Otani K, Mihara K. et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997; 7: 415-418.
30. Lane H-Y, Hu OY-P, Jann MW, et at. Dextromethorphan phenotypin and haloperidol disposition in schizophrenic patients. Psychiatry Res 1997; 69: 105-111.
31. Schmider J, Walter S, Sachse C, et al. Metabolism of antipsychotics and CYP2D6 genotype. Nauyn-Schmiedebergs Arch Pharmacol 1998; 357 (4:SS): R459.
32. Bareggi SR, Mauri M, Cavallaro R, Regazzetti MG, Moro AR. Factors affecting the clinical response to haloperidol therapy in schizophrenia. Clin Neuropharmacol 1990; 13(Suppl 1): S29-S34.
33. Chang WH. Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment? Psychopharmacol 1992; 106: 289-296.
34. Altamura AC. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia: with particular reference to drug resistance. Schizophr Res 1993; 8: 187-198.
35. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1991; 49: 234-240.
36. Grahame-Smith DG. The Lilly Prize Lecture 1996 'Keep on taking the tablets': pharmacological adaptation during long-term drug therapy. Br J Clin Pharmacol 1997; 44: 227-238.
37. Jerling M, Dahl M-L, Åberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996; 59: 423-428.
38. Bebbington PE. The content and context of compliance. Int Clin Pyschopharmacol 1995; 9: 41-50.
39. 2A receptor gene. Lancet 1995; 345: 281-282.
40. Lieberman JA, Alvir JM, Koreen A, et al. Psychobiological correlates of treatment response in schizophrenia. Neuroposychopharmacol 1996; 14 (3(Suppl): 13S-21S.
41. van Os J, Fahy TA, Jones P, et al. Psychobiological syndromes in the functional psychoses: associations with course and outcome. Psychol Med 1996; 26: 161-176.